Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9-10
pubmed:dateCreated
1999-4-15
pubmed:abstractText
Bryostatin-1 belongs to the family of macrocyclic lactones isolated from the marine bryozoan Bugula neritina and is a potent activator of protein kinase C (PKC). Bryostatin has been demonstrated to possess both in vivo and in vitro anti-leukaemic potential. In samples derived from chronic myeloid leukaemia (CML) patients, it has been demonstrated that bryostatin-1 induces a macrophage differentiation, suppresses colony growth in vitro and promotes cytokine secretion from accessory cells. We investigated the effect of bryostatin-1 treatment on colony-forming unit-granulocyte macrophage (CFU-GM) capacity in the presence of accessory cells, using mononuclear cells, as well as in the absence of accessory cells using purified CD34-positive cells. Cells were obtained from 14 CML patients as well as from nine controls. Moreover, CD34-positive cells derived from CML samples and controls were analysed for stem cell frequency and ability using the long-term culture initiating cell (LTCIC) assay at limiting dilution. Individual colonies derived from both the CFU-GM and LTCIC assays were analysed for the presence of the bcr-abl gene with fluorescence in situ hybridization (FISH) to evaluate inhibition of malignant colony growth. The results show that at the CFU-GM level bryostatin-1 treatment resulted in only a 1.4-fold higher reduction of CML colony growth as compared to the control samples, both in the presence and in the absence of accessory cells. However, at the LTCIC level a sixfold higher reduction of CML growth was observed as compared to the control samples. Analysis of the LTCICs at limiting dilution indicates that this purging effect is caused by a decrease in output per malignant LTCIC combined with an increase in the normal stem cell frequency. It is concluded that bryostatin-1 selectively inhibits CML growth at the LTCIC level and should be explored as a purging modality in CML.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-1375394, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-1498072, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-1656993, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-1712111, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-2033960, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-2265553, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-2310830, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-2333304, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-2386956, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-2989692, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-2996535, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-300256, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-3125421, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-3174627, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-3783162, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-6574315, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-7575530, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-7640233, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-7641182, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-7807010, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-7837820, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8043861, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8118022, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8160269, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8161775, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8165725, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8230254, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8379003, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8477194, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8499629, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8605966, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8947584, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-8950237, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-9009097, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-9440723, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188883-9533528
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
79
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1406-12
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.
pubmed:affiliation
Department of Haematology, Free University Hospital, Amsterdam.
pubmed:publicationType
Journal Article